Logo Geneseeq
  • Products
    • Solid Tumors
      • Pan-Cancer
      • Cancer Type-Specific
      • Minimal Residual Disease
    • Hematologic Malignancies
      • Pan-Cancer
      • Cancer Type-Specific
    • Cancer Early Detection
    • Hereditary Cancers
  • Services
    • Central Lab Testing
    • Local Testing Solutions
      • IVD Kit Solutions
      • RUO Kit Solutions
    • Research Services
      • DNA Sequencing
      • RNA Sequencing
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
    • Newsroom
    • Geneseeq Blogs
  • Join Us
  • Contact Us
  • Search

June 24, 2021

Geneseeq works with HUTCHMED and AstraZeneca in MET inhibitor approval for lung cancer patients in China

by GENESEEQ

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info@geneseeq.ca

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2026 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences

    FDA Cleared IVD kit